News
RGLS
8.16
0.00%
0.00
Regulus Acquired by Novartis, Delisted from Nasdaq
TipRanks · 06/25/2025 13:29
BRIEF-Novartis Completes Acquisition Of Regulus Therapeutics
Reuters · 06/25/2025 13:15
NOVARTIS AG - COMPLETES ACQUISITION OF REGULUS THERAPEUTICS
Reuters · 06/25/2025 13:13
Novartis announces expiration of Regulus Therapeutics tender offer
TipRanks · 06/25/2025 10:10
Novartis announces expiration of HSR waiting period of Regulus offer
TipRanks · 06/23/2025 17:18
Weekly Report: what happened at RGLS last week (0616-0620)?
Weekly Report · 06/23/2025 10:09
BRIEF-Novartis Announces Expiration Of Hart-Scott-Rodino Waiting Period Of Regulus Therapeutics Tender Offer
Reuters · 06/23/2025 05:02
Weekly Report: what happened at RGLS last week (0609-0613)?
Weekly Report · 06/16/2025 10:13
More
Webull provides a variety of real-time RGLS stock news. You can receive the latest news about Regulus Therapeu through multiple platforms. This information may help you make smarter investment decisions.
About RGLS
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. The Company is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, farabursen, an anti-miR next generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), is in Phase 1b clinical development. In addition to this program, the Company continues to advance and expand its internal discovery pipeline to identify potential product candidates. The microRNAs are naturally occurring ribonucleic acid (RNA) molecules that play a critical role in regulating key biological pathways. The ADPKD is among the common human monogenic disorders and a cause of end-stage renal disease.